{"id":"doi:10.1002/alz.14508","kind":"article","title":"The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study","authors":["Ashton NJ","Keshavan A","Brum WS","Andreasson U","Arslan B","Droescher M","Barghorn S","Vanbrabant J","Lambrechts C","Van Loo M","Stoops E","Iyengar S","Ji H","Xu X","Forrest-Hay A","Zhang B","Luo Y","Jeromin A","Vandijck M","Bastard NL","Kolb H","Triana-Baltzer G","Bali D","Janelidze S","Yang SY"],"author_count":44,"year":2025,"published":"2025-02-05","venue":"Alzheimer's & dementia : the journal of the Alzheimer's Association","cited_by":78,"doi":"10.1002/alz.14508","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1002/alz.14508","archive_url":"https://space-kitty.com/papers/doi:10.1002/alz.14508","updated":null,"pmid":"39907496","pmcid":"PMC11851162","openalex_id":null,"pdf_url":"https://europepmc.org/articles/PMC11851162/pdf","abstract":"Introduction The Alzheimer's Association Global Biomarker Standardization Consortium conducted a blinded case-control study to learn which phosphorylated tau (p-tau) assays provide the largest fold-changes in Alzheimer's disease (AD) versus non-AD and show commutability in measuring patient samples and candidate certified reference materials (CRMs). Methods Thirty-three different p-tau assays measured paired plasma and cerebrospinal fluid (CSF) from 40 participants (25 with \"AD pathology\" and 15 with \"non-AD pathology\" by CSF amyloid beta [Aβ]42/Aβ40 and p-tau181 criteria). Four CRMs were assessed. Results Plasma p-tau217 demonstrated higher fold-changes between AD and non-AD than other p-tau epitopes. Fujirebio LUMIPULSE G, UGOT IPMS, and Lilly MSD p-tau217 provided the highest fold-changes. Plasma p-tau217 showed the strongest correlations between plasma assays (rho = 0.81-0.97). The CRMs were not commutable across assays. Discussion Plasma p-tau217 showed larger fold-changes and better accuracy for detecting AD pathology in symptomatic individuals, with greater cross-platform agreement than other p-tau variants. Further work is needed to develop suitable CRMs facilitating cross-assay standardization. Highlights Paired plasma and cerebrospinal fluid (CSF) samples from twenty-five Alzheimer's disease (AD) and 15 non-AD patients were measured blind. Thirty-three plasma assays were compared, for phosphorylated tau-181 (p-tau181), 205, 212, 217 and 231. Plasma p-tau217 consistently had the highest fold-change and was best correlated between assays. Plasma-CSF correlations were weak to moderate. There was lack of commutability for four candidate reference materials.","abstract_license":"CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)","license":"CC-BY","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":[],"details":null,"provenance":"europepmc","attribution":"Abstract of \"The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study\" by Ashton NJ, Keshavan A, Brum WS et al., https://doi.org/10.1002/alz.14508, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","domain_slug":"medicine"}],"cited_in_dossiers":[]}